These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 15094222

  • 1. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis.
    Villanueva C, López-Balaguer JM, Aracil C, Kolle L, González B, Miñana J, Soriano G, Guarner C, Balanzó J.
    J Hepatol; 2004 May; 40(5):757-65. PubMed ID: 15094222
    [Abstract] [Full Text] [Related]

  • 2. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis.
    Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, Gatta A.
    Hepatology; 2000 Nov; 32(5):930-4. PubMed ID: 11050041
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
    Villanueva C, Aracil C, Colomo A, Hernández-Gea V, López-Balaguer JM, Alvarez-Urturi C, Torras X, Balanzó J, Guarner C.
    Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone.
    Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonato G, Angeli P, Gatta A.
    Hepatology; 1997 Jul; 26(1):34-9. PubMed ID: 9214449
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding.
    Villanueva C, Miñana J, Ortiz J, Gallego A, Soriano G, Torras X, Sáinz S, Boadas J, Cussó X, Guarner C, Balanzó J.
    N Engl J Med; 2001 Aug 30; 345(9):647-55. PubMed ID: 11547718
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis.
    Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell'Era A, Bosch J.
    Am J Gastroenterol; 2006 Mar 30; 101(3):506-12. PubMed ID: 16542287
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
    La Mura V, Abraldes JG, Raffa S, Retto O, Berzigotti A, García-Pagán JC, Bosch J.
    J Hepatol; 2009 Aug 30; 51(2):279-87. PubMed ID: 19501930
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.
    Villanueva C, Graupera I, Aracil C, Alvarado E, Miñana J, Puente Á, Hernandez-Gea V, Ardevol A, Pavel O, Colomo A, Concepción M, Poca M, Torras X, Reñe JM, Guarner C.
    Hepatology; 2017 May 30; 65(5):1693-1707. PubMed ID: 28100019
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers.
    Hernández-Gea V, Aracil C, Colomo A, Garupera I, Poca M, Torras X, Miñana J, Guarner C, Villanueva C.
    Am J Gastroenterol; 2012 Mar 30; 107(3):418-27. PubMed ID: 22334252
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria.
    Merkel C, Bolognesi M, Berzigotti A, Amodio P, Cavasin L, Casarotto IM, Zoli M, Gatta A.
    J Hepatol; 2010 Jan 30; 52(1):45-53. PubMed ID: 19914730
    [Abstract] [Full Text] [Related]

  • 18. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial.
    García-Pagán JC, Villanueva C, Albillos A, Bañares R, Morillas R, Abraldes JG, Bosch J, Spanish Variceal Bleeding Study Group.
    Gut; 2009 Aug 30; 58(8):1144-50. PubMed ID: 19218249
    [Abstract] [Full Text] [Related]

  • 19. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP).
    Merkel C, Marin R, Enzo E, Donada C, Cavallarin G, Torboli P, Amodio P, Sebastianelli G, Sacerdoti D, Felder M, Mazzaro C, Beltrame P, Gatta A.
    Lancet; 2009 Aug 30; 348(9043):1677-81. PubMed ID: 8973428
    [Abstract] [Full Text] [Related]

  • 20. Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy.
    Villanueva C, Aracil C, Colomo A, Lopez-Balaguer JM, Piqueras M, Gonzalez B, Torras X, Guarner C, Balanzo J.
    Aliment Pharmacol Ther; 2009 Feb 15; 29(4):397-408. PubMed ID: 19006538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.